Anti-HCV nucleoside derivatives

• US 6,660,721 B2
• Filed: 03/26/2002
• Issued: 12/09/2003
• Est. Priority Date: 05/23/2001
• Status: Expired due to Fees

• Current Assignee: Hoffmann-La Roche Incorporated (Roche Holding AG)
• Original Assignee: Hoffmann-La Roche Incorporated (Roche Holding AG)
• Inventors: Jiang, Wen-Rong, Martin, Joseph Armstrong, Hobbs, Christopher John, Devos, Rene Robert, Najera, Isabel, Merrett, John Herbert
• Primary Examiner(s): Wilson, James O.
• Assistant Examiner(s): Lewis, Patrick
• Application Number:
  US10/106,970
• Publication Number:
  US 20030083307A1
• Time in Patent Office: 623 Days
• Field of Search: 514/23, 514/42, 514/43, 514/45, 514/46, 514/49, 514/47, 514/48, 514/52, 536/18.7, 536/22.1, 536/28.1, 536/28.6, 536/28.7
• US Class Current: 514/45
• CPC Class Codes: A61K 31/7068 having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
• CPC Class Codes: A61K 31/7076 containing purines, e.g. adenosine, adenylic acid
• CPC Class Codes: A61K 31/708 having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
• CPC Class Codes: A61P 1/16 for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• CPC Class Codes: A61P 31/14 for RNA viruses

Abstract

The present invention comprises nucleoside derivatives for use in the treatment or prophylaxis of hepatitis C virus infections. In particular, the present invention discloses the novel use of known 2′-deoxy-2′-fluoro nucleoside derivatives as inhibitors of hepatitis C virus (HCV) RNA replication and pharmaceutical compositions of such compounds. The compounds of this invention have potential use as therapeutic agents for the treatment of HCV infections.

Claims

1. A method for the treatment of hepatitis C virus (HCV) infection comprising administering a therapeutically effective amount of a compound of formula I-a

wherein

R¹ is hydrogen or phosphate and

B is a 1-pyrimidinyl or 9-purinyl residue of formulae B1, B2 or B3

and pharmaceutically acceptable salts thereof.

2. The method of claim 1 wherein

B is 1-pyrimidinyl,

and pharmaceutically acceptable salts thereof.

3. The method of claim 1 wherein the compound is

2′

-deoxy-2′

-fluorocytidine,

9-(2-deoxy-2-fluoro-β

-D-ribofuranosyl)-2,6-diaminopurine,

2′

-deoxy-2′

-fluoroguanosine, or

2′

-deoxy-2′

-fluorocytidine 5′

-O-triphosphate mono lithium salt.